Class switch recombination and somatic hypermutation of virus- neutralizing antibodies are not essential for control of friend retrovirus infection

Journal of Virology

Volumn 89, Issue 2, 2015, Pages 1468-1473

  Kato, Maiko ^a   Tsuji Kawahara, Sachiyo ^a   Kawasaki, Yuri ^a   Kinoshita, Saori ^a   Chikaishi, Tomomi ^a,b   Takamura, Shiki ^a   Fujisawa, Makoto ^a   Kawada, Akira ^a   Miyazawa, Masaaki ^a  

^a KINKI UNIVERSITY   (Japan)

^b Unmet Medical Needs Pharma Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; FREUND ADJUVANT; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN M; MYELOID DIFFERENTIATION FACTOR 88; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EPITOPE MAPPING; FRIEND LEUKEMIA VIRUS; GERMINAL CENTER; IMMUNIZATION; IMMUNOGLOBULIN GENE; MOUSE; NONHUMAN; PASSIVE TRANSPORT; PROTEIN FUNCTION; RETROVIRUS INFECTION; SOMATIC HYPERMUTATION; VIREMIA; VIRUS GENOME; VIRUS RECOMBINATION; ANIMAL; BLOOD; DEFICIENCY; EXPERIMENTAL LEUKEMIA; FRIEND MURINE LEUKEMIA VIRUS; GENE REARRANGEMENT; IMMUNOLOGY; PASSIVE IMMUNIZATION; VIROLOGY; VIRUS INFECTION;

FRIEND MURINE LEUKEMIA VIRUS; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CYTIDINE DEAMINASE; FRIEND MURINE LEUKEMIA VIRUS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN M; LEUKEMIA, EXPERIMENTAL; MICE; RETROVIRIDAE INFECTIONS; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; TUMOR VIRUS INFECTIONS;

EID: 84920842302     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02293-14     Document Type: Article

References (18)

1. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, Clerici M. 2009. The "immunologic advantage" of HIV-exposed seronegative individuals. AIDS 23:161-175. http://dx.doi.org/10.1097/QAD.0b013e3283196a80.
2. Chesebro B, Miyazawa M, Britt WJ. 1990. Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol 8:477-499. http://dx.doi.org/10.1146/annurev.iy.08.040190.002401.
3. Miyazawa M, Tsuji-Kawahara S, Kanari Y. 2008. Host genetic factors that control immune responses to retrovirus infections. Vaccine 26:2981-2996. http://dx.doi.org/10.1016/j.vaccine.2008.01.004.
4. Persons DA, Paulson RF, Loyd MR, Herley MT, Bodner SM, Bernstein A, Correll PH, Ney PA. 1999. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet 23:159-165. http://dx.doi.org/10.1038/13787.
5. Tsuji-Kawahara S, Kawabata H, Matsukuma H, Kinoshita S, Chikaishi T, Sakamoto M, Kawasaki Y, Miyazawa M. 2013. Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for the regulation of retrovirus-induced myeloid leukemia development. J Virol 87:13760-13774. http://dx.doi.org/10.1128/JVI.02506-13.
6. + T cells. J Virol 88:1854-1855. http://dx.doi.org/10.1128/JVI.03271-13.
7. Miyazawa M, Fujisawa R, Ishihara C, Takei YA, Shimizu T, Uenishi H, Yamagishi H, Kuribayashi K. 1995. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. J Immunol 155:748-758.
8. + T cell-deficient mice against Friend retrovirus-induced disease. Int Immunol 18:183-198. http://dx.doi.org/10.1093/intimm/dxh361.
9. Browne EP, Littman DR. 2009. Myd88 is required for an antibody response to retroviral infection. PLoS Pathog 5:e1000298. http://dx.doi.org/10.1371/journal.ppat.1000298.
10. Kane M, Case LK, Wang C, Yurkovetskiy L, Dikiy S, Golovkina TV. 2011. Innate immune sensing of retroviral infection via Toll-like receptor 7 occurs upon viral entry. Immunity 35:135-145. http://dx.doi.org/10.1016/j.immuni.2011.05.011.
11. Browne EP. 2013. Toll-like receptor 7 inhibits early acute retroviral infection through rapid lymphocyte responses. J Virol 87:7357-7366. http://dx.doi.org/10.1128/JVI.00788-13.
12. Browne EP. 2011. Toll-like receptor 7 controls the anti-retroviral germinal center response. PLoS Pathog 7:e1002293. http://dx.doi.org/10.1371/journal.ppat.1002293.
13. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553-563. http://dx.doi.org/10.1016/S0092-8674(00)00078-7.
14. Tsuji-Kawahara S, Chikaishi T, Takeda E, Kato M, Kinoshita S, Kajiwara E, Takamura S, Miyazawa M. 2010. Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in Friend virus-infected mice. J Virol 84:6082-6095. http://dx.doi.org/10.1128/JVI.02516-09.
15. Ishihara C, Miyazawa Nishio MJ, Chesebro B. 1991. Induction of protective immunity to Friend murine leukemia virus in genetic nonresponders to virus envelope protein. J Immunol 146:3958-3963.
16. Hasenkrug KJ, Brooks DM, Chesebro B. 1995. Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci USA 92:10492-10495. http://dx.doi.org/10.1073/pnas.92.23.10492.
17. Halemano K, Guo K, Heilman KJ, Barrett BS, Smith DS, Hasenkrug KJ, Santiago ML. 2014. Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection. Proc Natl Acad Sci USA 111: 7759-7764. http://dx.doi.org/10.1073/pnas.1403361111.
18. Robertson MN, Miyazawa M, Mori S, Caughey B, Evans LH, Hayes SF, Chesebro B. 1991. Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and Western blotting. J Virol Methods 34:255-271. http://dx.doi.org/10.1016/0166-0934(91)90105-9.